Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression

Gynecologic Oncology

Volumn 92, Issue 2, 2004, Pages 559-567

  Torng, Pao Ling ^a   Mao, Tsui Lien ^a   Chan, Wing Yee ^a   Huang, Su Cheng ^a   Lin, Chin Tang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Immunohistochemistry; Metalloproteinase; Ovarian adenocarcinoma; Prognosis; Stroma; Tumor size

Indexed keywords

METALLOPROTEINASE; METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; TUMOR VOLUME;

EID: 0842332135     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.11.011     Document Type: Article

References (37)

1. General Health Statistics Health and vital statistics. Part 1:2001;87 Department of Health, Taiwan, ROC.
2. McGuire W.P., Hoskins W.J., Brady M.F.et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 23:1996;40-47.
3. Goodman M.T., Correa C.N., Tung K.H.et al. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer. 97:2003;2648-2659.
4. Bell K.A., Kurman R.J. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am. J. Surg. Pathol. 24:2000;1465-1479.
5. Zwart J., Geisler J.P., Geisler H.E. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma. Eur. J. Gynaecol. Oncol. 19:1998;225-228.
6. Simpson J.L., Bischoff F.Z. Heritability and molecular genetic studies of endometriosis. Ann. N.Y. Acad. Sci. 955:2002;239-251. [Discussion 293-5, 396-406].
7. Nagase H., Woessner J.F. Jr. Matrix metalloproteinases. J. Biol. Chem. 274:1999;21491-21494.
8. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 189:1999;300-308.
9. Collier I.E., Wilhelm S.M., Eisen A.Z.et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J. Biol. Chem. 263:1988;6579-6587.
10. Kolkenbrock H., Hecker-Kia A., Orgel D., Ulbrich N., Will H. Activation of progelatinase A and progelatinase A/TIMP-2 complex by membrane type 2-matrix metalloproteinase. Biol. Chem. 378:1997;71-76.
11. Schmalfeldt B., Prechtel D., Harting K.et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7:2001;2396-2404.
12. Wu X., Li H., Kang L., Li L., Wang W., Shan B. Activated matrix metalloproteinase-2 - A potential marker of prognosis for epithelial ovarian cancer. Gynecol. Oncol. 84:2002;126-134.
13. Davidson B., Goldberg I., Gotlieb W.H.et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin. Exp. Metastasis. 17:1999;799-808.
14. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature. 411:2001;375-379.
15. Afzal S., Lalani E.N., Poulsom R.et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum. Pathol. 29:1998;155-165.
16. Soini Y., Hurskainen T., Hoyhtya M., Oikarinen A., Autio-Harmainen H. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J. Histochem. Cytochem. 42:1994;945-951.
17. Soini Y., Paakko P., Autio-Harmainen H. Genes of laminin B1 chain, alpha 1 (IV) chain of type IV collagen, and 72-kd type IV collagenase are mainly expressed by the stromal cells of lung carcinomas. Am. J. Pathol. 142:1993;1622-1630.
18. Nomura H., Fujimoto N., Seiki M., Mai M., Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int. J. Cancer. 69:1996;9-16.
19. Boag A.H., Young I.D. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am. J. Pathol. 144:1994;585-591.
20. Autio-Harmainen H., Karttunen T., Hurskainen T., Hoyhtya M., Kauppila A., Tryggvason K. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab. Invest. 69:1993;312-321.
21. Afzal S., Lalani el N., Foulkes W.D.et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab. Invest. 74:1996;406-421.
22. Naylor M.S., Stamp G.W., Davies B.D., Balkwill F.R. Expression and activity of MMPS and their regulators in ovarian cancer. Int. J. Cancer. 58:1994;50-56.
23. Westerlund A., Apaja-Sarkkinen M., Hoyhtya M., Puistola U., Turpeenniemi-Hujanen T. Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecol. Oncol. 75:1999;91-98.
24. Russel P. Surface epithelial-stromal tumors of the ovary. Kurman R.J. Blaustein's pathology of the female genital tract. Fourth ed. 1994;705-782 Springer, New York.
25. Poste G., Fidler I.J. The pathogenesis of cancer metastasis. Nature. 283:1980;139-146.
26. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:2003;49-54.
27. Jiang X., Morland S.J., Hitchcock A., Thomas E.J., Campbell I.G. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res. 58:1998;1707-1712.
28. Chambers A.F., Naumov G.N., Vantyghem S.A., Tuck A.B. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2:2000;400-407.
29. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev., Cancer. 2:2002;563-572.
30. Sheu B.C., Lien H.C., Ho H.N.et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 63:2003;6537-6542.
31. Liotta L.A., Stetler-Stevenson W.G. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 51:1991;5054s-5059s.
32. Zhu B., Block N.L., Lokeshwar B.L. Interaction between stromal cells and tumor cells induces chemoresistance and matrix metalloproteinase secretion. Ann. N.Y. Acad. Sci. 878:1999;642-646.
33. Boyd R.S., Balkwill F.R. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br. J. Cancer. 80:1999;315-321.
34. DeClerck Y.A. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur. J. Cancer. 36:2000;1258-1268.
35. Davidson B., Goldberg I., Berner A., Kristensen G.B., Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin. Exp. Metastasis. 20:2003;161-169.
36. Kusano K., Miyaura C., Inada M.et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology. 139:1998;1338-1345.
37. Kohn E.C.F., Isaiah J., Fishman D., Jaffe R., Liotta L.A., Van Trappen P., Mills G.B., Trope C. Discussion: metastasis and angiogenesis in epithelial ovarian cancer. Gynecol. Oncol. 88:2003;S37-S42.